Overview

ProUrokinase in Mild IsChemic strokE (PUMICE)

Status:
Not yet recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the safety and efficacy of rhPro-UK (35mg) versus standard medical treatment in acute mild ischemic stroke within 4.5 hours of symptom onset.

Phase:

Phase 3

Details

Lead Sponsor:

Beijing Tiantan Hospital

Treatments:

Anticoagulants
Aspirin
Clopidogrel
Saruplase